Azeliragon (dihydrochloride)
Product Specifications
UNSPSC Description
Azeliragon dihydrochloride (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression in patients with mild Alzheimer’s disease (AD)[1]. Azeliragon dihydrochloride also can cross the blood-brain barrier (BBB)[2].
Target Antigen
Amyloid-β
Type
Reference compound
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Cancer; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/azeliragon-dihydrochloride.html
Smiles
CCN(CCCOC1=CC=C(C=C1)C2=CN(C(CCCC)=N2)C3=CC=C(C=C3)OC4=CC=C(C=C4)Cl)CC.Cl.Cl
Molecular Weight
605.04
References & Citations
[1]Bongarzone S, et al. Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective. J Med Chem. 2017 Sep 14;60(17):7213-7232.|[2]Burstein AH, et al. Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc Analysis. Clin Pharmacol Drug Dev. 2019 May;8(4):426-435.|[3]Chen Y, et al. RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol. 2008 Sep 15;181(6):4272-8.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-50682A/Azeliragon-dihydrochloride-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-50682A/
Clinical Information
Phase 3
CAS Number
1284150-65-7
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
BNC741969-100 100 µL
Anti-Thyroglobulin (Thyroidal Cell Marker) (r6E1), CF740 conjugate
Ask
View Details 